Myocarditis and pericarditis are inflammatory conditions of the heart, with symptoms including shortness of breath, palpitations and chest discomfort.
The mRNA vaccines from BioNTech/Pfizer and Moderna are possibly linked to uncommon cases of heart inflammation, according to analysis of 321 cases post-vaccination released Friday by the European Medicines Agency.
The security committee PRAC evaluated 145 cases of myocarditis and 138 cases of pericarditis after the BioNTech/Pfizer vaccine. For Modernas jab, PRAC analyzed 19 cases of each condition.
The committee also suggested limiting the Johnson & & Johnson vaccine marketing authorization so that individuals with a history of capillary leakage syndrome do not receive it. It encouraged including a side result warning for the serious condition, in which fluid leaks from small blood vessels causing swelling, low high blood pressure, blood thickening and low blood albumin levels.
By the end of May, around 177 million dosages of the BioNTech/Pfizer vaccine and 20 million doses of Modernas had been given in the European Economic Area.
PRAC advised upgrading the product info to raise and include this side impact awareness amongst healthcare personnel and vaccine receivers.
3 of such cases have been reported to the EMA, one in an individual with previous history of the syndrome, following the Johnson & & Johnson jab. All cases occurred within two days of vaccination; 2 of the three passed away. Since June 21, 18 million dosages of the single-shot vaccine have been administered worldwide.
From drug pricing, EMA, vaccines, pharma and more, our specialized reporters keep you on top of the topics driving the health care policy agenda.
PRAC advised that the item information for the Oxford/AstraZeneca vaccine include a cautioning to raise awareness of cases of Guillain-Barre syndrome (GBS) that may have been reported following vaccination.
All cases took place within two days of vaccination; 2 of the three died. As of June 21, 18 million doses of the single-shot vaccine have been administered worldwide.
This post belongs to POLITICOs premium policy service: Pro Health Care. From drug pricing, EMA, vaccines, pharma and more, our specialized reporters keep you on top of the topics driving the healthcare policy program. Email [email safeguarded] for a complimentary trial.
The syndrome triggers nerve swelling and can lead to discomfort, tingling, muscle weak point and difficulty strolling.
Presently, offered information “neither rules nor verifies out a possible association with the vaccine,” PRAC said. However given the severity of GBS, it encouraged cautioning individuals of cases.
